Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.8 SEK | +1.15% | +4.76% | +9.41% |
May. 06 | Humana Names Successor to Outgoing President/CEO | MT |
May. 06 | Humana AB Announces CEO Changes | CI |
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The stock, which is currently worth 2024 to 0.61 times its sales, is clearly overvalued in comparison with peers.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The group shows a rather high level of debt in proportion to its EBITDA.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.41% | 136M | B | ||
-17.59% | 2.39B | B- | ||
+2.74% | 1.46B | - | C+ | |
-27.12% | 1.43B | - | ||
+21.31% | 1.36B | B | ||
+31.77% | 809M | - | B | |
-10.00% | 435M | B- | ||
+234.05% | 424M | - | D+ | |
-3.59% | 341M | - | - | |
+46.62% | 95.92M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HUM Stock
- Ratings Humana AB